Acetohydroxamic acid [546-88-3] – general description and application

General description of Acetohydroxamic acid:

Acetohydroxamic acid (AHA) [546-88-3] also known under trade names Lithostat (US) or Uronefrex (EU) is a compound, structurally similar to urea. In a pure form, it is a white crystalline solid with melting point of 90-91 °C.[1] The structure of the hydroxamic acids was first brought to the attention by W. Lossen in 1869.[2] Few years later he observed, apparently by accident, that thermal decomposition of hydroxamic acid led to the isocyanate. This reaction was later named after him as Lossen rearrangement.[3]

The most general method of preparation is the reaction between ethylacetate or acetic anhydride and hydroxylamine in absolute alcohol. The reaction proceeds rapidly at room temperature, particularly in the presence of an equimolecular quantity of sodium alkoxide.[4] Alternatively, AHA can be prepared from acetyl chloride and hydroxylamine with sodium carbonate in ether/water.[5]

Application of Acetohydroxamic acid:

Acetohydroxamic acid is a potent urease inhibitor of bacterial urease activity, especially Helicobacter pylori.[6] It was found to be useful in treating urinary tract infections by preventing urine alkalization. Although this compound had severe side effects, such as teratogenicity, psychoneurologic and musculo-integumentary symptoms, it was approved by the FDA in 1983 to treat chronic urea-splitting urinary infections.[7] It is used, in addition to antibiotics or medical procedures, to treat chronic urea-splitting urinary infections.

It can be oxidized in situ to nitrosocarbonylmethane which reacts in Diels–Alder reaction with 1,3-dienes.[5] Acetohydroxamic acid is a good chelating agent for heavy metals[8] such as copper, iron, cobalt, nickel, chromium, manganese, uranium. It has been suggested as a partitioning agent for the separation of uranium and plutonium in nuclear fuel reprocessing.[9]

Product categorization (Chemical groups):

Main category:

Second level:


[1] D. C. Berndt, H. Shechter J. Org. Chem. 1964, 29, 916.
[2] H. Lossen Liebigs Ann. Chem. 1869, 150, 314.
[3] H. L. Yale Chem. Rev. 1943, 33, 209.
A. Miolati Chem. Ber. 1892, 25, 700.
H. Blatt, Org. Synth. 1963, 2, John Wiley & Sons, New York, NY.
[5] J. Fährmann, G. Hilt Angew. Chem. Int. Ed. 2021, 60, 20313.
[6] J. Goldie, S. J. O. Veldhuyzen van Zanten, S. Jalali, H. Richardson, R. H. Hunt J. Clin. Pathol. 1991, 44, 695.
[7] P. Kosikowska, L. Berlicki Expert Opin. Ther. Pat. 2011, 21, 945.
[8] B. Chatterjee Coord. Chem. Rev. 1978, 26, 281.
[9] J. E. Birkett, M. J. Carrott, O. D. Fox, C. J. Jones, C. S. Maher, C. V. Roube, R. J. Taylor and D. A. Woodhead J. Nucl. Sci. Technol. 2007, 44, 337.